Arcus Ventures

Arcus Ventures is a private equity firm in New York that invests in oncology-focused companies with advanced biopharmaceuticals. Founded 2007 in New York, United States by James B. Dougherty and Steven L. Soignet, this firm invests in early and late stage ventures. It usually invests in Series C, Series B, and Series A rounds. Its portfolio companies include Cleave Therapeutics, Exosome Diagnostics, XTuit Pharmaceuticals, TRACON Pharmaceuticals, and Epic Sciences. The company also finances new drug delivery platforms in development, device companies with products that have pre-marketing approval, and service companies with positive revenue.

Arcus Ventures is a private equity firm in New York that invests in oncology-focused companies with advanced biopharmaceuticals. Founded 2007 in New York, United States by James B. Dougherty and Steven L. Soignet, this firm invests in early and late stage ventures. It usually invests in Series C, Series B, and Series A rounds. Its portfolio companies include Cleave Therapeutics, Exosome Diagnostics, XTuit Pharmaceuticals, TRACON Pharmaceuticals, and Epic Sciences. The company also finances new drug delivery platforms in development, device companies with products that have pre-marketing approval, and service companies with positive revenue.

Arcus Ventures is a private equity firm in New York that invests in oncology-focused companies with advanced biopharmaceuticals. Founded 2007 in New York, United States by James B. Dougherty and Steven L. Soignet, this firm invests in early and late stage ventures. It usually invests in Series C, Series B, and Series A rounds. Its portfolio companies include Cleave Therapeutics, Exosome Diagnostics, XTuit Pharmaceuticals, TRACON PharmaceuticalsTRACON Pharmaceuticals, and Epic Sciences. The company also finances new drug delivery platforms in development, device companies with products that have pre-marketing approval, and service companies with positive revenue.

Arcus Ventures is a private equity firm in New York that invests in oncology-focused companies with advanced biopharmaceuticals. Founded 2007 in New York, United States by James B. Dougherty and Steven L. Soignet, this firm invests in early and late stage ventures. It usually invests in Series C, Series B, and Series A rounds. Its portfolio companies include Cleave Therapeutics, Exosome DiagnosticsExosome Diagnostics, XTuit Pharmaceuticals, TRACON Pharmaceuticals, and Epic Sciences. The company also finances new drug delivery platforms in development, device companies with products that have pre-marketing approval, and service companies with positive revenue.

Arcus Ventures is a private equity firm in New York that invests in oncology-focused companies with advanced biopharmaceuticals. Founded 2007 in New York, United StatesUnited States by James B. Dougherty and Steven L. Soignet, this firm invests in early and late stage ventures. It usually invests in Series C, Series B, and Series A rounds. Its portfolio companies include Cleave Therapeutics, Exosome Diagnostics, XTuit Pharmaceuticals, TRACON Pharmaceuticals, and Epic Sciences. The company also finances new drug delivery platforms in development, device companies with products that have pre-marketing approval, and service companies with positive revenue.

Arcus Ventures is a private equity firm in New York that invests in oncology-focused companies with advanced biopharmaceuticals. Founded 2007 in New York, United States by James B. Dougherty and Steven L. Soignet, this firm invests in early and late stage ventures. It usually invests in Series C, Series B, and Series A rounds. Its portfolio companies include Cleave Therapeutics, Exosome Diagnostics, XTuit Pharmaceuticals, TRACON Pharmaceuticals, and Epic SciencesEpic Sciences. The company also finances new drug delivery platforms in development, device companies with products that have pre-marketing approval, and service companies with positive revenue.